[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606433":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":72,"collaborators":11,"id":74,"slug":11,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":11,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":11,"enrollmentInfo":82,"targetDuration":11,"studyType":85,"phases":86,"briefSummary":89,"conditions":90,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CM336 injection","EXPERIMENTAL",null,[13],"Biological: CM336 Injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","CM336 Injection","subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Qian Jia","CONTACT","86+028-88610620","qianjia@keymedbio.com",[27,43,55],{"facility":28,"status":29,"city":30,"state":31,"zip":11,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Henan Cancer Hospital","RECRUITING","Zhengzhou","Henan","China",{"type":34,"coordinates":35},"Point",[36,37],113.64861,34.75778,{"lat":37,"lon":36},[40],{"name":41,"role":23,"phone":42,"phoneExt":11,"email":25},"Hu Zhou Henan Cancer Hospital","028-88610620",{"facility":44,"status":29,"city":45,"state":46,"zip":11,"country":32,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"Heping Hospital Affiliated to Changzhi Medical College","Changzhi","Shanxi",{"type":34,"coordinates":48},[49,50],113.10528,36.18389,{"lat":50,"lon":49},[53],{"name":54,"role":23,"phone":42,"phoneExt":11,"email":25},"Xuliang Shen Heping Hospital Affiliated to Changzhi Medical College",{"facility":56,"status":29,"city":57,"state":58,"zip":11,"country":32,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Blood Disease Hospital, Chinese Academy of Medical Sciences","Tianjin","Tianjin Municipality",{"type":34,"coordinates":60},[61,62],117.17667,39.14222,{"lat":62,"lon":61},[65,69],{"name":66,"role":23,"phone":67,"phoneExt":11,"email":68},"Lei Zhang","86+022-23608025","zhanglei1@ihcams.ac.cn",{"name":70,"role":23,"phone":67,"phoneExt":11,"email":71},"Jun Shi","shijun@ihcams.ac.cn",{"type":73,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100606433",false,"NCT07175493","A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia","A Phase 1\u002F2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Autoimmune Cytopenia","Inclusion Criteria:\n\n* Voluntary provision of written informed consent and ability to comply with protocol requirements.\n* Age ≥18 years, male or female.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.\n* Confirmed diagnosis of immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD), mixed autoimmune hemolytic anemia (mAIHA) or Evans Syndrome.\n* Relapsed or refractory autoimmune hemolytic anemia.\n\nExclusion Criteria:\n\n* Secondary ITP or AIHA caused by any reason. Subjects with positive autoimmune antibodies but without a clear diagnosis of any other autoimmune diseases are allowed to be enrolled.\n* Other types of AIHA or other types of cytopenia\n* History of critical diseases that, in the opinion of the investigator, may pose a risk to the safety of subjects or whose exacerbation during the study could compromise the efficacy or safety analysis of the results.\n* Received any treatment of anti-B Cell Maturation Antigen(BCMA) antibody.\n* Evaluated unsuitable to participant in this study by investigator.","ALL","18 Years",{"count":83,"type":84},158,"ESTIMATED","INTERVENTIONAL",[87,88],"PHASE1","PHASE2","To evaluate the efficacy and safety of CM336 (BCMA\u002FCD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia",[91,92,93,94],"Autoimmune Cytopenia","Immune Thrombocytopenia (ITP)","Autoimmune Hemolytic Anemia","Evans Syndrome","2025-12-09",{"date":97,"type":98},"2025-12-17","ACTUAL",{"date":100,"type":98},"2025-11-18",{"date":102,"type":84},"2028-11-18",{"name":5,"class":6},3]